SCHEMBL21148637

SCHEMBL21148637

CC1(C)O[C@H]2[C@@H](O1)[C@@H](CN1CCN(c3ccc(O)cc3)CC1)O[C@@H]1OC(C)(C)O[C@@H]12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.41
▸ DRD4 P21917 3/20 0.39
▸ DRD2 P14416 1/20 0.38
▸ DRD3 P35462 1/20 0.38
▸ HTR7 P34969 4/20 0.38
▸ HTR2C P28335 1/20 0.36
▸ KDM4E B2RXH2 5/20 0.36
▸ MAPT P10636 3/20 0.36
▸ PKM P14618 1/20 0.36
▸ CA2 P00918 2/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ GAA P10253 4/20 0.35
▸ POLB P06746 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137899 1.00 ALDH1A1 (0.41) ALDH1A1DRD4DRD2DRD3HTR7
SCHEMBL21148820 0.89 DRD4 (0.41) ALDH1A1DRD4DRD2DRD3KDM4E
SCHEMBL21149371 0.87 DRD2 (0.50) ALDH1A1DRD4DRD2DRD3HTR7
SCHEMBL21149372 0.87 DRD2 (0.50) ALDH1A1DRD4DRD2DRD3HTR7
SCHEMBL21148822 0.82 MAPT (0.42) ALDH1A1DRD4DRD2KDM4EMAPT
SCHEMBL21149325 0.77 ALDH1A1 (0.35) ALDH1A1DRD4DRD2DRD3MAPT
SCHEMBL20873302 0.77 DRD4 (0.39) ALDH1A1DRD4DRD2DRD3HTR7
SCHEMBL10190784 0.72 CA2 (0.45) ALDH1A1CA2CA1CA9
SCHEMBL20873246 0.69 DRD4 (0.44) ALDH1A1DRD4DRD2DRD3HTR7
SCHEMBL14114357 0.65 CA2 (0.50) ALDH1A1MAPTCA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885DRD4 4226/4885DRD2 4570/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885DRD4 4226/4885DRD2 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback